相关实验视频

Updated: Jan 11, 2026

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

通过与PLX51107结合,改善无遗传BRCAness的PARP抑制剂在膀癌中的疗效

Jutta Schmitz^1,2, Anna L Bartkowiak^1,2, Michael Rose^2,3,4,5

¹Department of Urology, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Germany.

Molecular oncology

|November 11, 2025

概括

新的研究表明,将Talazoparib (一种PARP抑制剂) 与PLX51107 (一种BET抑制剂) 结合起来,显示出治疗晚期泌尿腺癌 (UC) 的重大前景. 这种组合疗法可能有利于所有UC患者,无论之前的治疗方法或遗传突变如何.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

晚期泌尿腺癌 (UC) 需要超越传统化疗和免疫疗法的新疗法策略.
目前的多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 在UC中表现出有限的疗效,特别是在接受西斯普拉丁治疗的患者中,这凸显了改善患者选择或组合方法的需要.

研究的目的:

在UC模型中比较Olaparib和Talazoparib的疗效.
在UC中确定PARPi反应的新生物标志物.
为了研究将PARPi与BET抑制剂PLX51107结合起来,以加强UC治疗的协同潜力.

主要方法:

用PARPi治疗的UC细胞系的RNA测序.
分析实验和公共临床数据以确定反应预测因子.
在体外和有机体研究中评估了Talazoparib和PLX51107的组合,包括在抗西斯普拉丁模型中.

主要成果:

奥拉巴里布和塔拉佐巴里布在UC中表现出不同的分子标和免疫反应调节.
确定了SLFN5,SLFN11和OAS1作为潜在的UC特异性的PARPi反应生物标志物.
塔拉佐巴里布和PLX51107的组合显示出强大的协同作用,克服了西斯普拉丁的耐药性,并允许降低剂量以最大限度地降低对正常细胞的毒性.

结论:

塔拉佐巴里布和PLX51107的组合在各种UC模型中非常有效.
这种新的治疗策略扩大了Talazoparib对所有UC患者的适用性,不论Cisplatin预治疗或BRCAness状态如何.
协同作用背后的机制包括增强的DNA修复抑制,DNA复制中断和亡诱导.

关键词:

这是一种BET抑制剂.膀癌是一种癌症.这是一种PARP抑制剂.生物标志物生物标志物组合疗法治疗组合治疗.表观遗传学是指表观遗传学.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...